A registry of achondroplasia: a 6-year experience from the Czechia and Slovak Republic
Abstract Background Achondroplasia (ACH) is one of the most prevalent genetic forms of short-limbed skeletal dysplasia, caused by gain-of-function mutations in the receptor tyrosine kinase FGFR3. In August 2021, the C-type natriuretic peptide (CNP) analog vosoritide was approved for the treatment of...
Main Authors: | Martin Pesl, Hana Verescakova, Linda Skutkova, Jana Strenkova, Pavel Krejci |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-06-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-022-02374-x |
Similar Items
-
Achondroplasia: a comprehensive clinical review
by: Richard M. Pauli
Published: (2019-01-01) -
Achondroplasia in the Premature Infant: An Elusive Diagnosis in the Neonatal Intensive Care Unit
by: Kimberly E. Fagen, et al.
Published: (2017-01-01) -
Experiences of children and adolescents living with achondroplasia and their caregivers
by: Renée Shediac, et al.
Published: (2022-04-01) -
Severe achondroplasia due to two de novo variants in the transmembrane domain of FGFR3 on the same allele: A case report
by: Tadashi Nagata, et al.
Published: (2020-03-01) -
Impact of achondroplasia on Latin American patients: a systematic review and meta-analysis of observational studies
by: Virginia Fano, et al.
Published: (2022-01-01)